BioCryst Pharmaceuticals vs Travere Therapeutics
BCRX and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and TVTX compare
Travere Therapeutics is the larger company, worth 2.5 times as much as BioCryst Pharmaceuticals ($4.8B against $1.9B).
Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 68.7% for BioCryst Pharmaceuticals).
Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −40.9% at BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $1.9B | $4.8B |
| Share price | $7.50 | $51.10 |
| Change, 1 year | 5.9% | 48.1% |
| Change, 5 years | −39.9% | 76.0% |
| Beta (5Y) | 0.58 | 1.91 |
| Employees | 435 | 497 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 2 | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.0× (better) | 8.1× |
| P/B | – | 196× |
| EV/EBITDA | – | 197× |
| P/FCF | 5.1× | – |
| FCF yield | 19.5% | – |
| Fair value | – | $6.01 |
| Margin of safety | – | −751% |
| Growth | ||
| Revenue growth (TTM) | 68.7% | 77.1% (better) |
| Revenue growth, 5Y average | 118% (better) | 19.9% |
| Profitability | ||
| Gross margin | 97.8% | 98.6% (better) |
| Operating margin | −33.3% | −6.8% (better) |
| Net margin | −40.9% | −7.4% (better) |
| FCF margin | 39.7% | – |
| Return on equity | – | −152% |
| Financial health | ||
| Interest coverage | −4.2× (better) | −4.3× |
| Current ratio | 2.32 | 4.05 (better) |
| Altman Z-score | −3.83 | 2.29 (better) |
| Piotroski F-score | 7 | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 112% |
| Held by insiders | 1.9% | 1.6% |
| Insider net buying, 12 months | −$4.1M (better) | −$110M |
| Short interest, % of float | 11.0% | 10.3% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.